# Hims & Hers Health, Inc.: overview

HIMS · NYSE · CIK 1773751 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hims.md) · [Financials](/companies/hims/financials.md) · [Filings](/companies/hims/filings.md) · [Insiders](/companies/hims/insiders.md)

Latest reported revenue: [$753.2m](/filings/0001773751-26-000163.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001773751-26-000163).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [402](/filings/0001773751-25-000354.md) | [481 d](/filings/0001773751-26-000022.md) | [586](/filings/0001773751-26-000076.md) | [545](/filings/0001773751-26-000163.md) | [599](/filings/0001773751-25-000354.md) | [618 d](/filings/0001773751-26-000022.md) | [608](/filings/0001773751-26-000076.md) | [753](/filings/0001773751-26-000163.md) |
| Gross margin | % | [79.2%](/filings/0001773751-25-000354.md) | [76.8% d](/filings/0001773751-26-000022.md) | [73.5%](/filings/0001773751-26-000076.md) | [76.4%](/filings/0001773751-26-000163.md) | [73.8%](/filings/0001773751-25-000354.md) | [71.9% d](/filings/0001773751-26-000022.md) | [65.2%](/filings/0001773751-26-000076.md) | [63.8%](/filings/0001773751-26-000163.md) |
| Operating margin | % | [5.6%](/filings/0001773751-25-000354.md) | [3.9% d](/filings/0001773751-26-000022.md) | [9.9%](/filings/0001773751-26-000076.md) | [4.9%](/filings/0001773751-26-000163.md) | [2.0%](/filings/0001773751-25-000354.md) | [1.5% d](/filings/0001773751-26-000022.md) | [(12.9%)](/filings/0001773751-26-000076.md) | [(12.9%)](/filings/0001773751-26-000163.md) |
| Net margin | % | [18.8%](/filings/0001773751-25-000354.md) | [5.4% d](/filings/0001773751-26-000022.md) | [8.4%](/filings/0001773751-26-000163.md) | [7.8%](/filings/0001773751-26-000163.md) | [2.6%](/filings/0001773751-25-000354.md) | [3.3% d](/filings/0001773751-26-000022.md) | [(15.1%)](/filings/0001773751-26-000163.md) | [(11.5%)](/filings/0001773751-26-000163.md) |
| Diluted EPS | $ per share | [0.32](/filings/0001773751-25-000354.md) | not reported | [0.20](/filings/0001773751-26-000076.md) | [0.17](/filings/0001773751-26-000163.md) | [0.06](/filings/0001773751-25-000354.md) | not reported | [(0.40)](/filings/0001773751-26-000076.md) | [(0.37)](/filings/0001773751-26-000163.md) |
| Free cash flow | $m | [79.4 d](/filings/0001773751-25-000354.md) | [59.5 d](/filings/0001773751-26-000022.md) | [50.1](/filings/0001773751-26-000076.md) | [(69.5) d](/filings/0001773751-26-000163.md) | [79.3 d](/filings/0001773751-25-000354.md) | [(2.6) d](/filings/0001773751-26-000022.md) | [53.1](/filings/0001773751-26-000076.md) | [(68.2) d](/filings/0001773751-26-000163.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [272](/filings/0001773751-24-000025.md) | [527](/filings/0001773751-25-000062.md) | [872](/filings/0001773751-26-000022.md) | [1,477](/filings/0001773751-26-000022.md) | [2,348](/filings/0001773751-26-000022.md) |
| Gross margin | % | [75.2%](/filings/0001773751-24-000025.md) | [77.6%](/filings/0001773751-25-000062.md) | [82.0%](/filings/0001773751-26-000022.md) | [79.5%](/filings/0001773751-26-000022.md) | [73.8%](/filings/0001773751-26-000022.md) |
| Operating margin | % | [(42.3%)](/filings/0001773751-24-000025.md) | [(13.0%)](/filings/0001773751-25-000062.md) | [(3.4%)](/filings/0001773751-26-000022.md) | [4.2%](/filings/0001773751-26-000022.md) | [4.5%](/filings/0001773751-26-000022.md) |
| Net margin | % | [(39.6%)](/filings/0001773751-24-000025.md) | [(12.5%)](/filings/0001773751-25-000062.md) | [(2.7%)](/filings/0001773751-26-000022.md) | [8.5%](/filings/0001773751-26-000022.md) | [5.5%](/filings/0001773751-26-000022.md) |
| Diluted EPS | $ per share | [(0.58)](/filings/0001773751-24-000025.md) | [(0.32)](/filings/0001773751-25-000062.md) | [(0.11)](/filings/0001773751-26-000022.md) | [0.53](/filings/0001773751-26-000022.md) | [0.51](/filings/0001773751-26-000022.md) |
| Free cash flow | $m | not reported | [(33.7)](/filings/0001773751-25-000062.md) | [47.0](/filings/0001773751-26-000022.md) | [198](/filings/0001773751-26-000022.md) | [57.4](/filings/0001773751-26-000022.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hims/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-28 | [Boughton Soleil](/insiders/1837817.md) | Chief Legal Officer, Officer | Sale (S) | 3,462 | $27.60 | $95.6k | [Form 4](/filings/0001837817-26-000021.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $995.2m | 28,703,514 |  | Added +2,366,356 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $469.4m | 13,539,700 | Call | Added +688,800 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $366.1m | 10,559,314 |  | Added +375,501 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $330.8m | 9,541,384 |  | Added +201,673 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $312.2m | 9,004,900 | Put | Reduced −1,562,300 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $282.4m | 8,145,699 |  | Added +685,676 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $248.0m | 7,152,498 |  | Reduced −1,736,590 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $210.4m | 6,067,800 | Call | Reduced −847,900 |
| [Divisadero Street Capital Management, LP](/funds/1901865.md) | 2026-06-30 | $208.3m | 6,009,505 |  | Added +5,539,672 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $197.0m | 5,681,832 |  | Added +483,053 |

## Recent filings

[All 1,286 filings](/companies/hims/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-07 | 16:13 ET | [8-K](/filings/0001773751-26-000220.md) | 5.02 Departure or appointment of officers or directors | 0001773751-26-000220 |
| 2026-08-31 | 21:49 ET | [SCHEDULE 13D/A](/filings/0001193125-26-377305.md) | Ownership report, active investor, amended | 0001193125-26-377305 |
| 2026-08-10 | 16:17 ET | [10-Q](/filings/0001773751-26-000163.md) | Quarterly report, period 2026-06-30 | 0001773751-26-000163 |
| 2026-08-10 | 16:08 ET | [8-K](/filings/0001773751-26-000161.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001773751-26-000161 |
| 2026-07-17 | 16:13 ET | [8-K](/filings/0001773751-26-000149.md) | 5.02 Departure or appointment of officers or directors | 0001773751-26-000149 |
| 2026-07-01 | 17:02 ET | [8-K](/filings/0001773751-26-000146.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001773751-26-000146 |
| 2026-06-15 | 17:02 ET | [8-K](/filings/0001773751-26-000096.md) | 5.07 Shareholder vote results | 0001773751-26-000096 |
| 2026-06-02 | 06:02 ET | [8-K](/filings/0001773751-26-000091.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001773751-26-000091 |
| 2026-05-21 | 17:05 ET | [8-K](/filings/0001193125-26-234847.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-234847 |
| 2026-05-19 | 08:17 ET | [8-K](/filings/0001193125-26-229749.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229749 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001773751-26-000022.md), filed Feb 23, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/08f4a78e-99e3-4ad1-9bba-55318e62b2bc)

## About the filer

- CIK: 1773751
- Tickers: HIMS
- Exchange: NYSE
- SIC code: 8011 Services-Offices & Clinics of  Doctors of  Medicine
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:02 ET. No prices; not investment advice.